Literature DB >> 3283084

Venocclusive disease of the liver after allogeneic bone marrow transplantation in man.

G Ganem1, M F Saint-Marc Girardin, M Kuentz, C Cordonnier, G Marinello, C Teboul, F Braconnier, J P Vernant, D Dhumeaux, J P Le Bourgeois.   

Abstract

One hundred and fifty-one consecutive patients underwent allogeneic bone marrow transplantation (B.M.T.) following high-dose chemotherapy and single dose total body irradiation (T.B.I.) for hematologic malignancies between September 1980 and December 1985. All patients included in this study were treated using a 60 Co beam to deliver a prescribed dose of 10 Gy to the mid-plane of the abdomen. Total body irradiation was performed the day before B.M.T. The mean instantaneous dose-rate was 3.5 cGy/min (range: 2.6 to 4.7). The real dose received was measured using thermoluminescent dosimeters (lithium borate). The difference between the doses delivered to the liver and to the mid-plane of the abdomen did not exceed 5%. The mean real dose delivered to the reference point was 10 Gy (range 8.3 to 11.7). Ninety five per cent of the patients received a dose ranging from 9.1 Gy to 10.9 Gy. High-dose cyclophosphamide was given to 126 patients with a "standard-risk" of relapse (60 mg/kg on day 5 and 4 before B.M.T.). Chemotherapy was intensified by the addition of other drugs in 25 patients with "higher-risk" of relapse. We analyzed the effect of the following pretransplant characteristics on the subsequent posttransplant development of V.O.D.: age, sex, ASAT and/or ALAT before conditioning regimen, diagnosis and status of malignant disease, history of liver disease, interval between diagnosis of hematologic malignancy and B.M.T., conditioning regimen (i.e., classical or intensified) and dose delivered to the liver during T.B.I. Seventeen patients were classified as having clinical V.O.D. giving a prevalence of 11.2%. In the first 2 months following B.M.T., death occurred respectively in 9 of 17 (53%) and 23 of 134 (17%) patients with and without clinical V.O.D. Univariate analysis showed that four characteristics were significantly related to an increased prevalence of V.O.D.: sex (11/62 females vs 6/89 males; p less than 0.05); history of liver disease (7/28 vs 10/117 patients without antecedent; p less than 0.01); ASAT and/or ALAT levels greater than 1.5 upper normal limit (11/49 vs 6/102 patients with levels less than 1.5; p less than 0.01) and intensified conditioning regimen (6/25 vs 11/126 patients with classical regimen; p less than 0.05). The conditioning regimen and history of liver disease were highly correlated to transaminases levels. Only two factors, transaminases levels and female sex, remained significantly associated with V.O.D. after multivariate analysis.

Entities:  

Mesh:

Year:  1988        PMID: 3283084     DOI: 10.1016/0360-3016(88)90009-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.

Authors:  Ajoy Dias; Saad J Kenderian; Gustavo F Westin; Mark R Litzow
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

2.  Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study.

Authors:  V M Whitehead; M L Bernstein; R Vega; T Vats; P Dyment; T J Vietti; J Krischer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies.

Authors:  Maria Giuseppina Cefalo; Palma Maurizi; Annalisa Arlotta; Maria Scalzone; Giorgio Attinà; Antonio Ruggiero; Riccardo Riccardi
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

Review 4.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

5.  Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.

Authors:  Partow Kebriaei; Kaci Wilhelm; Farhad Ravandi; Mark Brandt; Marcos de Lima; Stefan Ciurea; Laura Worth; Susan O'Brien; Deborah Thomas; Richard E Champlin; Hagop Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-01-10

6.  High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG-99702).

Authors:  Kellie J Nazemi; Violet Shen; Jonathan L Finlay; James Boyett; Mehmet Kocak; Deborah Lafond; Sharon L Gardner; Roger J Packer; H Stacy Nicholson
Journal:  Pediatr Blood Cancer       Date:  2016-05-20       Impact factor: 3.167

7.  Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients.

Authors:  Y Belkacémi; F Pène; E Touboul; B Rio; V Leblond; N C Gorin; A Laugier; C Gemici; M Housset; M Ozsahin
Journal:  Strahlenther Onkol       Date:  1998-02       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.